The Netherlands Cancer Institute’s Post

September 24 is World Cancer Research Day! Interventional oncology, as the fourth pillar of cancer care, plays a crucial role in supporting cancer patients. At the European Conference of Interventional Oncology, we continue to showcase the latest advancements in IO treatments and research, further expanding the arsenal of cancer-fighting strategies. Check out some of the lectures and sessions from #ECIO2024 focused on cutting-edge IO research: Essentials of oncology ➡️ https://t.ly/Jgrue Meet the PI: upcoming research ➡️ https://t.ly/gkqEw Addressing the lack of data and registries in paediatrics ➡️ https://t.ly/f5UFQ Artificial intelligence for interventional oncology ➡️ https://t.ly/3054b Best at ECIO: incoming evidence for liver tumours ➡️ https://t.ly/BzwYn Technical developments and clinical results in the treatment of liver tumours ➡️ https://t.ly/IIGHM Extrahepatic application for IO: revisiting the old and embracing the new ➡️ https://t.ly/BtxN5 #interventionaloncology #interventionalradiology #WorldCancerResearchDay #IRad

The April American Society of Clinical Oncology (ASCO) Plenary Series are here - Toni Choueiri https://lnkd.in/gwGsFvc3 #oncodaily #oncology #cancer #research #ASCO #ASCOPlenarySeries

LUNG CANCER Cocktail with Science 5th Edition The treatment of lung cancer is evolving rapidly. Our annual meeting provides an update on data from major national and international conferences, allowing experts and participants to discuss the latest findings, put them in context and really understand how they affect our daily practice. Participants will have the opportunity to engage with faculty members who will share their views on the main controversies surrounding the management of lung cancer. Leading experts in the treatment of lung cancer will share their ideas and knowledge with congress participants with the ultimate goal of mutual enrichment. PRESIDENT OF THE CONFERENCE Giuseppe Lo Russo, MD PhD Thoracic Unit, Medical Oncology Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT #GiuseppeLoRusso #lungcancer #oncology #thoracicunit Fondazione IRCCS Istituto Nazionale dei Tumori di Milano

LUNG CANCER Cocktail with Science 5th Edition The treatment of lung cancer is evolving rapidly. Our annual meeting provides an update on data from major national and international conferences, allowing experts and participants to discuss the latest findings, put them in context and really understand how they affect our daily practice. Participants will have the opportunity to engage with faculty members who will share their views on the main controversies surrounding the management of lung cancer. Leading experts in the treatment of lung cancer will share their ideas and knowledge with congress participants with the ultimate goal of mutual enrichment. PRESIDENT OF THE CONFERENCE Giuseppe Lo Russo, MD PhD Thoracic Unit, Medical Oncology Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT #lungcancer

Our METALLICA Study, now published in e Clinical Medicine (The Lancet) , unveils findings on preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer. Titled "Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA)" this multicentre, open-label, single-arm study signifies a notable advancement in patient care. This study delves into the efficacy of prophylactic metformin in mitigating hyperglycaemia occurrence among patients battling HR+/HER2−/PIK3CA-mutated advanced breast cancer (ABC). We are proud to announce that the #METALLICAtrial will also be presented at the upcoming ESMO - European Society for Medical Oncology Breast congress in Berlin. Read the article here: https://lnkd.in/d9bGNdpU Find more information about the METALLICA clinical trial: https://lnkd.in/d-D4NNEU #ESMOBreast2024 #breastcancer #Oncology

Join the ultimate face-off between Paolo Tarantino and Aakash Desai, MD, MPH as they review the latest in breast and thoracic oncology! American Society of Clinical Oncology (ASCO) #ASCO24 #BreastCancer #Cancer #OncoDaily #Oncology #ThoracicOncology

📢 In the second episode of our animated video series, Prof. Maria Vittoria Dieci continues the patient case on ER+/HER2- metastatic breast cancer. 🔍 Explore what follows after prescribing elacestrant and gain insights from patient-reported outcomes in the EMERALD trial. Catch up on the first video with Prof. François-Clément Bidard on optimizing treatment selection and sequencing for ER+/HER2- metastatic breast cancer. Key Takeaways: ✅ Elacestrant shows a manageable safety profile and meaningful clinical benefit. ✅ Treatment choice post-elacestrant should consider prior treatments, disease burden, and tumour biology. https://ow.ly/4mFc50SIsKB *This educational programme is supported by an Independent Educational Grant from Menarini Stemline Oncology.*

ASCO24 Updates: How PRIME-ROSE is Expanding Access to Precision Cancer Medicine American Society of Clinical Oncology (ASCO) Kjetil Tasken (Oslo University Hospital) #oncodaily #oncology #cancer #research #ASCO24 #ASCO2024

American Society of Clinical Oncology (ASCO) 24 Updates: Dr. Thejus Thayyil Jayakrishnan on Tumor Microbiome in Pancreatic Cancer The American Society of Clinical Oncology (ASCO) Annual Meeting, held from May 31 to June 4 in Chicago, is a premier event in oncology, bringing together oncologists, researchers, and healthcare professionals to explore the latest advancements in cancer research and treatment. This year, OncoDaily covered ASCO 2024 on-site, conducting interviews with leading researchers. Dr. Thejus Jayakrishnan from Cleveland Clinic discussed the differences in tumor microbiomes between early-onset and average-onset pancreatic adenocarcinoma. For details, visit: https://lnkd.in/es5h2Hew #PancreaticCancer #OncoDaily #Oncology #Cancer #Health #Medicine #ASCO24

Join us tomorrow for CASE OF THE MONTH #30 The 'DIFFICULT DIAPHRAGM' in OVARIAN Cancer with #PaulSugarbaker Live 'X' chat/ tweet chat 🤔 How far can the limits be pushed with diaphragmatic resection in ovarian cancer? 🙄 What if the visceral pleura is contiguously involved? 🙃 Should the diaphragm be reconstructed? And how? Join us tomorrow; Follow #PSOGICASE Friday, 7th June, 2024 5.00 pm CET 11.00 am EST 8.30 pm IST 12. 00 pm 🇧🇷 7.30 pm 🇸🇦 4.00 pm 🇬🇧 🇮🇪 ISSPP e.V. | International Society for the Study of Pleura and Peritoneum European Society of Surgical Oncology (ESSO) European School of Peritoneal Surface Oncology (ESPSO) International Journal of Gynecological Cancer (IJGC) #ovariancancer #cytoreductivesurgery #HIPEC #advancedovariancancer